Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

X
Trial Profile

A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Cabozantinib Versus Sunitinib in Participants With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabozantinib (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms CheckMate-9ER; CM 9ER
  • Sponsors Bristol-Myers Squibb; Exelixis; Ono Pharmaceutical; Takeda
  • Most Recent Events

    • 06 Feb 2024 According to an Exelixis Media Release, 4-year follow-up data from this trial presented at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU) to be held from January 25-27 in San Francisco, California.
    • 27 Jan 2024 Results of a modelling analysis assessing relationship between clinical outcomes, treatment and early deterioration in HRQoL dimensions presented at the 2024 Genitourinary Cancers Symposium
    • 27 Jan 2024 Results of updated efficacy (n=651) in intent-to-treat (ITT) patients and by International Metastatic RCC Database Consortium (IMDC) risk, and safety with extended 55-month follow-up of the CheckMate 9ER trial, presented at the 2024 Genitourinary Cancers Symposium.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top